Hospital
Doctors Hospital of Riverside LLC
Doctors Hospital of Riverside LLC was paid $37.65M by Medicaid between Dec 2019 and Dec 2024, across 225 billing codes. Its largest line is 99283, emergency room visit (moderate) — 55% of everything it billed.
33Billing provider infoDOCTORS HOSPITAL OF RIVERSIDE LLC
RIVERSIDE, CA 92503
RIVERSIDE, CA 92503
33aNPI1124596382assigned 11/06/2018
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.65M
24GClaims913,659
24DCodes billed225
24AFirst – last monthDec 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#78 of 410
Median peer was paid$6.90M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 16 | $731.60 | |
| 2020 | 125,787 | $4.57M | |
| 2021 | 153,494 | $6.04M | |
| 2022 | 209,082 | $8.67M | |
| 2023 | 223,040 | $9.54M | |
| 2024incomplete | 202,240 | $8.82M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 55% | 68,802 | 59,248 | $20.74M |
| 0450 | Emergency room services | 26% | 45,849 | 39,021 | $9.80M |
| G0378 | Hospital observation service, per hour | 3.3% | 3,486 | 2,250 | $1.25M |
| 0762 | 1.8% | 2,186 | 1,329 | $661K | |
| Z7502 | 1.5% | 14,690 | 14,344 | $547K | |
| 99499 | 1.4% | 7,129 | 5,753 | $518K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.3% | 15,514 | 14,802 | $492K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.2% | 8,942 | 8,465 | $442K |
| 99221 | <1% | 1,445 | 1,389 | $227K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18,965 | 17,145 | $177K |
| 96379 | <1% | 25,606 | 23,137 | $175K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,074 | 3,846 | $151K |
213 more codes
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,762 | $148K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 10,444 | $144K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,374 | $122K |
| 0750 | <1% | 800 | $113K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,268 | $103K |
| 0360 | <1% | 953 | $103K | |
| 80053 | Comprehensive metabolic panel | <1% | 49,838 | $98K |
| 99284 | Emergency room visit (serious) | <1% | 2,020 | $95K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 10,884 | $92K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 53,240 | $81K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,638 | $63K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,122 | $63K |
| 71045 | Radiologic examination, chest; single view | <1% | 26,632 | $59K |
| Z7610 | <1% | 4,193 | $54K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,140 | $50K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 16,771 | $49K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,224 | $44K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,481 | $42K |
| 99218 | <1% | 240 | $35K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,041 | $31K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 486 | $30K |
| 0710 | <1% | 1,599 | $30K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,405 | $30K |
| 99070 | <1% | 47,786 | $24K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,425 | $24K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 354 | $24K |
| 81025 | <1% | 14,929 | $22K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 498 | $21K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,231 | $21K |
| 83690 | <1% | 19,996 | $19K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 17,786 | $19K |
| 84484 | <1% | 17,771 | $18K | |
| 83880 | <1% | 7,761 | $18K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,670 | $18K |
| 88312 | <1% | 1,540 | $18K | |
| 88313 | <1% | 1,487 | $17K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,927 | $17K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,560 | $17K |
| 59025 | Fetal non-stress test | <1% | 2,791 | $17K |
| J3490 | Unclassified drugs | <1% | 3,868 | $16K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,612 | $14K |
| 0250 | <1% | 5,297 | $14K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 342 | $13K |
| 82553 | <1% | 8,602 | $12K | |
| 76801 | <1% | 1,762 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,681 | $12K |
| 76830 | Ultrasound, transvaginal | <1% | 1,291 | $11K |
| 81003 | <1% | 26,565 | $11K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,169 | $11K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 353 | $10K |
| 47562 | <1% | 54 | $10K | |
| 93971 | <1% | 982 | $10K | |
| 87400 | <1% | 11,431 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 914 | $9K |
| 82150 | <1% | 10,474 | $9K | |
| 90715 | <1% | 1,579 | $9K | |
| 74018 | <1% | 3,271 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,074 | $8K |
| 70486 | <1% | 446 | $7K | |
| 82550 | <1% | 9,075 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 942 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,440 | $7K |
| 83605 | <1% | 6,455 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,435 | $6K |
| 85730 | <1% | 8,358 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,961 | $6K |
| 87420 | <1% | 4,048 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,954 | $6K |
| 72100 | <1% | 1,560 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 905 | $6K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 323 | $6K |
| 99217 | <1% | 212 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 270 | $6K |
| 93307 | <1% | 553 | $6K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 348 | $5K |
| 0270 | <1% | 1,520 | $5K | |
| 84703 | <1% | 3,388 | $5K | |
| 85610 | <1% | 9,269 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,609 | $5K |
| 82947 | <1% | 5,840 | $4K | |
| 73630 | <1% | 1,742 | $4K | |
| 73564 | <1% | 1,576 | $4K | |
| 73610 | <1% | 1,739 | $4K | |
| 12001 | <1% | 775 | $4K | |
| 88304 | <1% | 465 | $4K | |
| 73130 | <1% | 1,577 | $4K | |
| 0510 | <1% | 107 | $4K | |
| 86850 | <1% | 1,236 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,182 | $4K |
| 73030 | <1% | 1,551 | $4K | |
| E0110 | Crutches, forearm, includes crutches of various materials, adjustable or fixed, pair, complete with tips and handgrips | <1% | 1,437 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 977 | $4K |
| 99224 | <1% | 61 | $3K | |
| 93970 | <1% | 193 | $3K | |
| 87040 | <1% | 2,899 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,869 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 429 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 687 | $3K |
| 29125 | <1% | 805 | $3K | |
| 72131 | <1% | 143 | $3K | |
| 73110 | <1% | 1,068 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,479 | $3K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 604 | $3K |
| 81001 | <1% | 9,768 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,803 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,466 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 587 | $3K |
| 86901 | <1% | 2,556 | $3K | |
| 84702 | <1% | 2,118 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 836 | $2K |
| 99199 | Unlisted special service, procedure or report | <1% | 55 | $2K |
| 86900 | <1% | 2,548 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,666 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,336 | $2K |
| 82948 | <1% | 3,212 | $2K | |
| 86140 | <1% | 3,727 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,275 | $2K |
| 29540 | <1% | 833 | $2K | |
| 82140 | <1% | 1,414 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,345 | $1K |
| 83735 | <1% | 3,782 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,605 | $1K |
| 71250 | <1% | 58 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 139 | $1K |
| 29530 | <1% | 423 | $1K | |
| 72040 | <1% | 454 | $1K | |
| 87070 | <1% | 279 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,800 | $919.53 |
| 82010 | <1% | 1,119 | $909.55 | |
| 84145 | <1% | 600 | $902.22 | |
| 73140 | <1% | 505 | $848.94 | |
| 85379 | <1% | 1,179 | $814.08 | |
| 73590 | <1% | 484 | $792.46 | |
| 82803 | <1% | 439 | $764.15 | |
| 94760 | <1% | 581 | $751.35 | |
| 87088 | <1% | 781 | $704.23 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 686 | $695.96 |
| 76870 | <1% | 153 | $640.43 | |
| 73080 | <1% | 380 | $600.32 | |
| 12011 | <1% | 67 | $588.49 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 299 | $588.48 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 16 | $588.39 |
| 29515 | <1% | 190 | $569.87 | |
| 86328 | <1% | 23 | $562.38 | |
| 29505 | <1% | 174 | $561.16 | |
| 81015 | <1% | 5,755 | $555.27 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 803 | $555.17 |
| 80076 | <1% | 2,901 | $536.44 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 105 | $517.48 |
| 71101 | <1% | 177 | $517.46 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,957 | $491.32 |
| 80061 | Lipid panel | <1% | 976 | $483.64 |
| 73090 | <1% | 304 | $472.20 | |
| 84100 | <1% | 2,609 | $439.79 | |
| 76770 | <1% | 96 | $398.14 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 468 | $395.77 |
| 94799 | <1% | 374 | $371.94 | |
| 73562 | <1% | 162 | $345.80 | |
| 84550 | <1% | 521 | $318.06 | |
| 73502 | <1% | 145 | $304.32 | |
| 84439 | <1% | 504 | $302.52 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 537 | $266.19 |
| 12002 | <1% | 54 | $232.02 | |
| 85652 | <1% | 1,384 | $218.84 | |
| 85027 | <1% | 462 | $218.37 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 52 | $209.76 |
| 29130 | <1% | 178 | $206.04 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 69 | $198.64 |
| 72080 | <1% | 45 | $192.69 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 179 | $191.17 |
| 73620 | <1% | 75 | $188.13 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 152 | $188.04 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 352 | $187.79 |
| 85007 | <1% | 894 | $178.94 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 260 | $162.95 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 164 | $153.09 |
| 83550 | <1% | 364 | $140.30 | |
| 83540 | <1% | 368 | $119.72 | |
| 10060 | <1% | 60 | $118.20 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 114 | $107.84 |
| 36600 | <1% | 164 | $94.31 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 143 | $87.42 |
| 87205 | <1% | 15 | $65.20 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 85 | $49.93 |
| 82746 | <1% | 66 | $41.84 | |
| 83615 | <1% | 40 | $36.74 | |
| 82728 | <1% | 29 | $32.34 | |
| 82607 | <1% | 83 | $31.98 | |
| 86803 | <1% | 40 | $20.12 | |
| 73560 | <1% | 14 | $18.22 | |
| 87081 | <1% | 47 | $18.20 | |
| 86705 | <1% | 37 | $16.60 | |
| 73120 | <1% | 12 | $16.07 | |
| 86709 | <1% | 37 | $15.86 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 236 | $12.45 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 14 | $9.04 |
| A4217 | Sterile water/saline, 500 ml | <1% | 13 | $6.18 |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg | <1% | 92 | $3.86 |
| 0272 | <1% | 354 | $1.61 | |
| A9270 | Non-covered item or service | 0% | 352 | $0.00 |
| 87340 | 0% | 39 | $0.00 | |
| 0271 | 0% | 340 | $0.00 | |
| 86920 | 0% | 36 | $0.00 | |
| 86593 | 0% | 12 | $0.00 | |
| 0370 | 0% | 212 | $0.00 | |
| 73552 | 0% | 26 | $0.00 | |
| 0258 | 0% | 27 | $0.00 | |
| 94762 | 0% | 14 | $0.00 | |
| 86592 | 0% | 12 | $0.00 | |
| 29105 | 0% | 58 | $0.00 | |
| J2598 | Injection, vasopressin, 1 unit | 0% | 15 | $0.00 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 0% | 14 | $0.00 |
| 10061 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHEUNG, ERIC (ATTORNEY)
| Provider | Location | Paid |
|---|---|---|
| Nephrology Associates | Santa Rosa, CA | $1.59M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.